Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521538 | 0.88 | HSD11B1 (0.45) | GRM2GRM3HSD11B1REN | |
| SCHEMBL5654759 | 0.85 | DRD2 (0.38) | SIGMAR1HSD11B1OPRM1PKM | |
| SCHEMBL23027974 | 0.84 | HSD11B1 (0.44) | GRM2GRM3HSD11B1L3MBTL1 | |
| SCHEMBL15820250 | 0.83 | HSD11B1 (0.43) | GRM2GRM3HSD11B1OPRM1L3MBTL1 | |
| SCHEMBL4511972 | 0.82 | SIGMAR1 (0.45) | SIGMAR1MAOAMAOB | |
| SCHEMBL1798916 | 0.81 | L3MBTL1 (0.42) | HSD11B1OPRM1PKMACHEL3MBTL1 | |
| SCHEMBL8217404 | 0.81 | PPARG (0.44) | SIGMAR1OPRM1L3MBTL1 | |
| SCHEMBL4512069 | 0.81 | TSHR (0.41) | MAOB | |
| SCHEMBL5399569 | 0.81 | TACR1 (0.48) | HSD11B1 | |
| SCHEMBL20862455 | 0.79 | MAOA (0.40) | GRM2GRM3SIGMAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | GRM2 4606/4885GRM3 2997/4885SIGMAR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.